Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

The PI3K/Akt signaling pathway is a key pathway in cell proliferation, growth, survival, protein synthesis, and glucose metabolism. It has been recognized recently that inhibiting this pathway might provide a viable therapy for cancer. A series of bis(morpholino-1,3,5-triazine) derivatives were prepared and optimized to provide the highly efficacious PI3K/mTOR inhibitor 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 26 (PKI-587). Compound 26 has shown excellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models when administered intravenously. The structure-activity relationships and the in vitro and in vivo activity of analogues in this series are described.

[1]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[2]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[3]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[4]  N. Brooijmans,et al.  Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. , 2009, Journal of medicinal chemistry.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  R. Abraham,et al.  Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[7]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[8]  Steven C. Kim,et al.  A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity. , 2006, Combinatorial chemistry & high throughput screening.

[9]  L. Schriml,et al.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.

[10]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[11]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[12]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[13]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[14]  T. Halazonetis,et al.  Emerging common themes in regulation of PIKKs and PI3Ks , 2009, The EMBO journal.

[15]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[16]  D. Goldsmith,et al.  Mammalian Target of Rapamycin (mTOR) Inhibitors , 2011, Drug safety.

[17]  R. Abraham,et al.  ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. , 2009, Journal of medicinal chemistry.

[18]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[19]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[20]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[21]  S. Hirono,et al.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.

[22]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[23]  G. Mills,et al.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. , 2008, Cancer research.

[24]  R. Abraham,et al.  Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. , 2010, Journal of medicinal chemistry.

[25]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.